NGEN — Nervgen Pharma Balance Sheet
0.000.00%
Last trade - 00:00
- CA$178.26m
- CA$151.85m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Cash and Short Term Investments | 4.11 | 5.6 | 16.9 | 22.5 | 11.7 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.122 | 0.063 | 0.064 | 0.027 | 0.25 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 6.26 | 6.2 | 17.4 | 23.1 | 12.5 |
Net Property, Plant And Equipment | — | 0.002 | 0.003 | 0.295 | 0.2 |
Net Intangible Assets | |||||
Total Assets | 6.77 | 6.68 | 17.9 | 23.9 | 13.2 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 0.924 | 0.755 | 1.08 | 10.2 | 15.1 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 0.924 | 0.755 | 1.08 | 10.4 | 15.2 |
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 5.84 | 5.92 | 16.8 | 13.5 | -2.01 |
Total Liabilities & Shareholders' Equity | 6.77 | 6.68 | 17.9 | 23.9 | 13.2 |
Total Common Shares Outstanding |